17 November 2016 Stevenage, UK – 17 November 2016 – Auspherix, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of organogold antibacterials, today announced further strengthening of its Management team, with Dr Neil Miller transitioning to Chief Executive Officer (CEO) from Chief Scientific Officer (CSO), and the Company announcing two […]
This author has yet to write their bio.Meanwhile lets just say that we are proud speedbird contributed a whooping 30 entries.
Entries by speedbird
The Auspherix team will be attending Bio-Europe. To meet with them, email firstname.lastname@example.org
Dr Neil Miller, CSO of Auspherix, will be presenting at the World Anti-Microbial Resistance Congress 2016. To meet him, email email@example.com.
Auspherix, an early stage anti-infectives company, today announces that it has been shortlisted for the ‘Start-Up UK Company of the Year’ category of the inaugural Biotech and Money 2016 Awards. Auspherix was nominated for the award and selected as a shortlisted finalist for its focus on developing new antibiotics in the fight against antimicrobial resistance and […]
4 July 2016 Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope. William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy. He is an […]
19 May 2016 Auspherix, an early stage anti-infectives company, today welcomes the O’Neill report on antimicrobial resistance “Tackling Drug-Resistant Infections Globally” which calls for large pharmaceutical companies to participate in the development of new treatments. Research has almost halted in the past 25 years because antibiotics are expensive to develop and provide relatively small returns. Dr […]
Members of the Auspherix team attended BioTrinity.
Co-founder of Auspherix Ltd. and VP Biology, Dr Dagmar Alber, has left the business to pursue new opportunities. Dagmar’s expertise and passion has been pivotal to Auspherix’s success. We thank Dagmar for her contribution and wish her every success for the future.
Dr Neil Miller, CSO of Auspherix, attended.
Auspherix, an early stage anti-infectives company, today announces that it has signed the BEAM Alliance’s call to governements and industry to work in parallel to take comprehensive action against drug-resistant infections, launched today at the World Economic Forum in Davos, Switzerland. Full release below. GLOBAL PHARMACEUTICAL INDUSTRY CALLS ON GOVERNMENTS TO WORK WITH THEM TO BEAT […]